Table 1

Patient population and control subjects used for the sPLA2 measurements.
Group
 n (F/M)
 Age yrs ± sd
 MS Onset yrs ± sd
 MS Duration yrs ± sd
 βIF
 GA
 None
Active
 12 (8/4)
 38.2 ± 9.5
 29.5 ± 8.9
 7.3 ± 4.5
 9
 1
 2
Stable
 32 (25/7)
 43.6 ± 8.1
 33.4 ± 8.6
 10.6 ± 9.3
 15
 3
 14
Control
 14 (9/5)
 37.5 ± 9.0
 -
 -
 -
 -
 -

The means of subject age, age of MS onset, duration of the disease, and ongoing therapies are listed. F/M = female/male; βIF = beta-interferon; GA = glatiramer acetate; sd = standard deviation.

Cunningham et al. Journal of Neuroinflammation 2006 3:26   doi:10.1186/1742-2094-3-26